China

China is experiencing significant demographic shifts, and these are spurring its emergence as a new player in innovative health care, says AXA IM's Cinney Zhang.

NAV down 10.7%

Share price is up 14.19% year-to-date

Painful to invest long-term now

T. Rowe Price's Wenli Zheng discusses how their China Evolution Equity Strategy arguably has a a unique design among China equity strategies

Targets long-term total NAV return of 15%

Responsible for one-third of emissions

'All companies will be making that move'

Lockdowns continue to weigh

China, US and Europe